Latest Biotech News

Eli Lilly agreed to acquire Centessa Pharmaceuticals for $6.3 billion to expand its neuroscience and sleep-disorder pipeline, front-loading the deal to secure programs led by orexin receptor 2...

Biogen moved to secure commercial immunology revenue by agreeing to acquire Apellis Pharmaceuticals for roughly $5.6 billion upfront. The transaction brings Apellis’ approved assets, led by...

Merck entered a multi-program antibody discovery pact with Infinimmune, potentially worth up to $838 million in upfront and milestones. Under the agreement, Merck will receive human antibody...

Novartis agreed to buy Excellergy, adding anti-IgE asset Exl-111 to its pipeline as the pharma continues expanding immunology capabilities through early-stage acquisitions. Exl-111 is currently in...

The Cancer Vaccine Coalition, partnering with the V Foundation for Cancer Research, awarded $1 million to UT MD Anderson Cancer Center for a Phase II breast cancer recurrence trial. The...

United Therapeutics reported that its second Phase III trial in idiopathic pulmonary fibrosis (IPF) met endpoints for Tyvaso (treprostinil), strengthening the company’s case for a supplemental NDA...

A CAR-T cell therapy from Wugen received FDA Breakthrough Therapy designation, according to reports from Washington University School of Medicine in St. Louis. The program is focused on a...

Roche won U.S. FDA 510(k) clearance for new lab automation modules, while also receiving CE marking for a blood donor screening assay. The Cobas c 703 and Cobas ISE Neo units expand throughput...

Alltrna, a tRNA therapy startup, received clearance to begin its first clinical trial, the company said. The trial launch marks a step into human testing for a platform approach in which a single...

ICON partnered with Advarra to build an integrated, AI-driven site network model designed to streamline clinical trial operations and reduce startup delays. The partnership connects ICON’s trial...

Kailera Therapeutics moved to the public markets, filing plans for an IPO to fund its obesity-focused pipeline after a run of very large private rounds. The company’s lead asset, weekly ribupatide...

Eli Lilly expanded its AI-driven drug development footprint by signing a commercialization and discovery collaboration with Insilico Medicine. Lilly will pay $115 million upfront and can make...

Rocket Pharmaceuticals received FDA approval for Kresladi, its gene therapy for leukocyte-adhesion deficiency type 1 (LAD1), an ultra-rare inherited immunodeficiency that can be fatal in infants...

United Therapeutics’ Tyvaso cleared another key late-stage milestone in idiopathic pulmonary fibrosis after a second Phase III trial hit its endpoints. The company is positioning for a potential...

Memorial Sloan Kettering researchers engineered a new uPAR-directed CAR T-cell therapy intended to expand cell therapy targeting beyond conventional antigens in solid tumors. The work centers on...

Novartis moved to expand its allergy and immunology pipeline by acquiring Excellergy. The purchase targets Exl-111, an anti-IgE antibody currently in Phase I testing, with potential applications...

Viridian Therapeutics disclosed top-line Phase III results for elegrobart (VRDN-003), an insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody in active thyroid eye disease. Patients...

Roche secured FDA 510(k) clearance for two Cobas Pro Integrated Solutions lab automation units—Cobas c 703 and Cobas ISE Neo—aimed at increasing throughput and reducing workflow friction in...

Canada’s PhenoTips partnered with five clinical institutions to launch the CIPHER network, an initiative funded with C$5.4 million from Genome Canada to accelerate AI genomic medicine. The program...

ICON teamed with Advarra to create an integrated, AI-driven site network model aimed at reducing clinical trial start-up delays. The partnership connects ICON’s trial services operations with...